U.S. markets closed
  • S&P 500

    3,666.72
    -2.29 (-0.06%)
     
  • Dow 30

    29,969.52
    +85.73 (+0.29%)
     
  • Nasdaq

    12,377.18
    +27.82 (+0.23%)
     
  • Russell 2000

    1,848.70
    +10.67 (+0.58%)
     
  • Crude Oil

    45.91
    +0.27 (+0.59%)
     
  • Gold

    1,845.50
    +4.40 (+0.24%)
     
  • Silver

    24.23
    +0.09 (+0.36%)
     
  • EUR/USD

    1.2154
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    0.9200
    -0.0280 (-2.95%)
     
  • GBP/USD

    1.3462
    +0.0009 (+0.07%)
     
  • USD/JPY

    103.7910
    -0.0690 (-0.07%)
     
  • BTC-USD

    19,511.40
    +59.90 (+0.31%)
     
  • CMC Crypto 200

    383.76
    +9.36 (+2.50%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,765.51
    -43.86 (-0.16%)
     

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Fate Therapeutics, Inc.
·2 min read

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 5:30 p.m. ET to report its second quarter 2020 financial results and provide a corporate update.

In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 8295527. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com